Entasis Therapeutics Holdings Inc. (ETTX)
| Market Cap | 104.65M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -53.84M |
| Shares Out | 29.96M |
| EPS (ttm) | -2.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $3.00 |
| Previous Close | $2.95 |
| Change ($) | 0.05 |
| Change (%) | 1.69% |
| Day's Open | 2.97 |
| Day's Range | 2.77 - 3.10 |
| Day's Volume | 570,822 |
| 52-Week Range | 1.61 - 5.56 |
WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of nove...
WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of nove...
WALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of nove...
WALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of nove...
WALTHAM, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of n...
Proceeds to support the ongoing ATTACK Phase 3 registration clinical trial Proceeds to support the ongoing ATTACK Phase 3 registration clinical trial
WALTHAM, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of no...
Entasis Therapeutics (ETTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
WALTHAM, Mass., July 06, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of no...
WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of no...
WALTHAM, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and devel...
Wall Street sell-side analysts are positive about Ekso Bionics Holdings Inc (NASDAQ:EKSO) and Entasis Therapeutics Holdings Inc (NASDAQ:ETTX), even though their holdings have lost more than 59...
WALTHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and deve...
CEO Dr. Manos Perros participated in Industry Panel today CEO Dr. Manos Perros participated in Industry Panel today
GENEVA and WALTHAM, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- The Global Antibiotic Research and Development Partnership (GARDP), a not for profit organization developing new treatments for ...
WALTHAM, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of n...
Entasis Therapeutics Holdings Inc. (ETTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
About ETTX
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. It is involved in developing Sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that has completed Phase II clinical trial for the treatment of multi-drug resistant Acinetobacter infections; Zoliflodacin, a novel orally administered molecule that has completed Phase II... [Read more...]
| Industry Biotechnology | IPO Date Sep 26, 2018 |
| CEO Dr. Manoussos Perros | Employees 48 |
| Stock Exchange NASDAQ | Ticker Symbol ETTX |
Financial Performance
In 2019, ETTX's revenue was $7.00 million, an increase of 40.00% compared to the previous year's $5.00 million. Losses were -$43.85 million, 4.17% more than in 2018.
Analyst Forecasts
According to 7 analysts, the average rating for ETTX stock is "Buy." The 12-month stock price forecast is 6.50, which is an increase of 116.67% from the latest price.